{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:56:26Z","timestamp":1792716986489,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>The Food and Drug Administration approved two disease\u2010modifying treatments (DMTs) for Alzheimer's disease (AD), aducanumab and lecanemab, with limited clinical impact but significant biomarker changes. Identifying suitable candidates for these DMTs outside randomized clinical trials (RCTs) remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cross\u2010sectional study, conducted in an Italian tertiary centre for cognitive disorders, aimed to evaluate how the RCT eligibility criteria for DMT treatments applies to participants with early AD. The broader Cummings et\u00a0al. (\n                      <jats:italic>Journal of Prevention of Alzheimer's Disease<\/jats:italic>\n                      , 2021, 2023) criteria and the clinical differences between DMT candidates were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study involved 408 participants (mean age 71.1\u2009\u00b1\u20098.5\u2009years, 48% male) with a clinical diagnosis of mild cognitive impairment (161\/408, 39.5%) or mild dementia (247\/408, 60.5%). Amongst them, 169 individuals (41%) showed positive\n                      <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>\n                      pathology biomarkers. Eligibility\n                      <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>\n                      assessment revealed 14 patients eligible for aducanumab (3.43% of 408) and 28 for lecanemab (6.86% of 408). Following Cummings' real\u2010world criteria, aducanumab eligibility increased to 9.56%, whereas lecanemab eligibility rose to 8.33%. Applying selection criteria to only the amyloid positive (169 out of 408), the selection for\n                      <jats:styled-content style=\"fixed-case\">DMTs<\/jats:styled-content>\n                      was 8.3% for aducanumab and 16.5% for lecanemab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Amongst subjects diagnosed with mild AD and mild cognitive impairment in a tertiary centre for cognitive disorders, only a small percentage of patients using RCT diagnostic criteria are eligible for DMT. The application of Cummings criteria strongly increased the DMT candidates. Nevertheless, the majority of patients with cognitive disorders have been excluded from DMTs approved so far.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.16534","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:29:12Z","timestamp":1730791752000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real\u2010word study on aducanumab and lecanemab"],"prefix":"10.1111","volume":"32","author":[{"given":"G.","family":"Logroscino","sequence":"first","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"},{"name":"Department of Translational Biomedicine and Neurosciences (DiBraiN) University of Bari Aldo Moro  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Urso","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-0842","authenticated-orcid":false,"given":"V.","family":"Gnoni","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9366-1582","authenticated-orcid":false,"given":"A.","family":"Giugno","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vilella","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Castri","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging Pia Fondazione \u2018Card. G. Panico\u2019  Tricase Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Barone","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-7983","authenticated-orcid":false,"given":"S.","family":"Nigro","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zecca","sequence":"additional","affiliation":[{"name":"Department of Clinical Research in Neurology, Centre for Neurodegenerative Diseases and the Aging Brain University of Bari \u2018Aldo Moro\u2019, \u2018Pia Fondazione Cardinale G. Panico\u2019  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"De Blasi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging Pia Fondazione \u2018Card. G. Panico\u2019  Tricase Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-6442","authenticated-orcid":false,"given":"A.","family":"Introna","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neurosciences (DiBraiN) University of Bari Aldo Moro  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad005"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17390"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17530"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5789"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15286"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.41"},{"issue":"3","key":"e_1_2_10_12_1","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment","volume":"8","author":"Hlavka JP","year":"2019","journal-title":"Rand Health Q"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.7249\/RR2272"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7586"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70013-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.07.004"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.07.010"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(23)00208-8"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0485-0"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:17:48Z","timestamp":1737937068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/ene.16534"],"URL":"https:\/\/doi.org\/10.1111\/ene.16534","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"2024-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16534"}}